{"id":9680,"date":"2025-12-28T22:29:45","date_gmt":"2025-12-28T13:29:45","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4552\/"},"modified":"2026-08-23T13:45:13","modified_gmt":"2026-08-23T04:45:13","slug":"company-4552","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4552\/","title":{"rendered":"JCR PHARMACEUTICAL CO"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4552","DATE":"2026-01-09","longName":"JCR Pharmaceuticals Co., Ltd.","company_name_ja":"\uff2a\uff23\uff32\u30d5\u30a1\u30fc\u30de(\u682a)","fullTimeEmployees":985,"address":"","phone":"","website":"https:\/\/www.jcrpharm.co.jp","industry":"Drug Manufacturers - General","sector":"Healthcare","regularMarketPrice":707,"financialCurrency":"","marketCap":86242,"fiftyTwoWeekLow":386,"fiftyTwoWeekHigh":824,"epsTrailingTwelveMonths":17.870000000000001,"epsForward":0,"bookValue":0,"totalRevenue":40319000000,"OperatingIncome":556000000,"operatingMargins":1.3799999999999999,"NetIncome":2178000000,"profitMargins":5.4000000000000004,"ebitda":0,"trailingPE":0,"forwardPE":19.30639,"priceToBook":1.7909752000000001,"returnOnEquity":4.6399999999999997,"recommendationMean":2.6666699999999999,"recommendationKey":"hold","targetMeanPrice":600,"numberOfAnalystOpinions":6,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:39:58.402810\", \"ticker\": \"4552\", \"ticker_full\": \"4552.T\", \"company_name\": \"JCR PHARMACEUTICAL CO\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 0, \"buy\": 1, \"hold\": 5, \"sell\": 0, \"strong_sell\": 0, \"total_analysts\": 6, \"recommendation_key\": \"hold\", \"recommendation_mean\": 2.66667}, \"target_prices\": {\"has_data\": true, \"current\": 479.0, \"high\": 900.0, \"low\": 430.0, \"mean\": 600.0, \"median\": 540.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": {\"date\": \"2026-10-29\", \"eps_estimate\": 18.67, \"eps_actual\": null, \"surprise_pct\": null}, \"future_count\": 1, \"past_earnings\": [{\"date\": \"2026-07-29\", \"eps_estimate\": -11.27, \"eps_actual\": -15.64, \"surprise_pct\": -38.78}, {\"date\": \"2026-01-28\", \"eps_estimate\": -1.07, \"eps_actual\": 0.27, \"surprise_pct\": 125.23}, {\"date\": \"2025-10-30\", \"eps_estimate\": 18.67, \"eps_actual\": 18.51, \"surprise_pct\": -0.88}, {\"date\": \"2025-07-29\", \"eps_estimate\": 4.36, \"eps_actual\": -4.48, \"surprise_pct\": -202.76}, {\"date\": \"2025-05-13\", \"eps_estimate\": -31.54, \"eps_actual\": -33.8, \"surprise_pct\": -7.17}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 41.21, \"institution_pct\": 9.26, \"major_holders\": [{\"label\": \"\", \"value\": 41.21}, {\"label\": \"\", \"value\": 9.26}, {\"label\": \"\", \"value\": 15.75}, {\"label\": \"\", \"value\": 35.0}], \"institutional_holders\": [{\"holder\": \"Legato Capital Management LLC\", \"shares\": 10901, \"date_reported\": \"2022-09-30\", \"pct_held\": 0.01, \"pct_change\": 1.0, \"value\": 5221579}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 1066475, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.82, \"pct_change\": 5.62, \"value\": 510841525}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 715249, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.55, \"pct_change\": 0.0, \"value\": 342604271}, {\"holder\": \"VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap \", \"shares\": 303500, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.23, \"pct_change\": 11.38, \"value\": 145376500}, {\"holder\": \"SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF\", \"shares\": 163644, \"date_reported\": \"2026-05-31\", \"pct_held\": 0.13, \"pct_change\": 4.76, \"value\": 78385476}, {\"holder\": \"VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.\", \"shares\": 91432, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.07, \"pct_change\": -5.09, \"value\": 43795928}, {\"holder\": \"VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Total World Stock Index Fd.\", \"shares\": 62900, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.05, \"pct_change\": 0.0, \"value\": 30129100}, {\"holder\": \"WisdomTree Trust-WisdomTree Japan SmallCap Dividend Fund\", \"shares\": 64600, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.05, \"pct_change\": -4.01, \"value\": 30943400}, {\"holder\": \"SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF\", \"shares\": 39000, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.03, \"pct_change\": 1.56, \"value\": 18681000}, {\"holder\": \"SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E\", \"shares\": 24400, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.02, \"pct_change\": 0.0, \"value\": 11687600}, {\"holder\": \"VANGUARD WORLD FUND-Vanguard ESG International Stock ETF\", \"shares\": 12100, \"date_reported\": \"2026-05-31\", \"pct_held\": 0.01, \"pct_change\": 0.0, \"value\": 5795900}]}}","dividendRate":0,"dividendYield":2.8199999999999998,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":10,"get_dividend_history_year2":20,"get_dividend_history_year3":20,"get_dividend_history_year4":20,"get_dividend_history_year5":22,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:46:54.931009\", \"ticker\": \"4552\", \"ticker_full\": \"4552.T\", \"company_name\": \"JCR PHARMACEUTICAL CO\", \"company_info\": {\"name_en\": \"JCR PHARMACEUTICAL CO\", \"long_name\": \"JCR Pharmaceuticals Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - General\", \"website\": \"https:\/\/www.jcrpharm.co.jp\", \"employees\": 985, \"country\": \"Japan\", \"city\": \"Ashiya\", \"address\": \"3-19 Kasuga-cho\", \"description\": \"JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 525.2, \"deviation\": 0.72, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 511.56, \"deviation\": 3.41, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 491.15, \"deviation\": 7.71, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 583.85, \"deviation\": -9.39, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 40319000000.0, \"revenue_fmt\": \"\u00a5403\u5104\", \"gross_profit\": 30185000000.0, \"gross_profit_fmt\": \"\u00a5302\u5104\", \"operating_income\": 556000000.0, \"operating_income_fmt\": \"\u00a56\u5104\", \"ebit\": 3622000000.0, \"ebit_fmt\": \"\u00a536\u5104\", \"net_income\": 2178000000.0, \"net_income_fmt\": \"\u00a522\u5104\", \"eps\": 17.87, \"operating_margin\": 1.38, \"total_assets\": 109236000000.0, \"total_assets_fmt\": \"\u00a51092\u5104\", \"total_equity\": 46938000000.0, \"total_equity_fmt\": \"\u00a5469\u5104\", \"total_debt\": 53892000000.0, \"total_debt_fmt\": \"\u00a5539\u5104\", \"total_cash\": 14007000000.0, \"total_cash_fmt\": \"\u00a5140\u5104\", \"equity_ratio\": 42.97, \"de_ratio\": 1.15, \"current_ratio\": 1.16, \"operating_cf\": -135000000.0, \"operating_cf_fmt\": \"-\u00a51\u5104\", \"investing_cf\": -12504000000.0, \"investing_cf_fmt\": \"-\u00a5125\u5104\", \"financing_cf\": 13305000000.0, \"financing_cf_fmt\": \"\u00a5133\u5104\", \"free_cf\": -11716000000.0, \"free_cf_fmt\": \"-\u00a5117\u5104\", \"net_margin\": 5.4, \"roe\": 4.64, \"roa\": 1.99}, {\"year\": 2025, \"revenue\": 33072000000.0, \"revenue_fmt\": \"\u00a5331\u5104\", \"gross_profit\": 22169000000.0, \"gross_profit_fmt\": \"\u00a5222\u5104\", \"operating_income\": -6220000000.0, \"operating_income_fmt\": \"-\u00a562\u5104\", \"ebit\": -5828000000.0, \"ebit_fmt\": \"-\u00a558\u5104\", \"net_income\": -4460000000.0, \"net_income_fmt\": \"-\u00a545\u5104\", \"eps\": -36.02, \"operating_margin\": -18.81, \"total_assets\": 104849000000.0, \"total_assets_fmt\": \"\u00a51048\u5104\", \"total_equity\": 47339000000.0, \"total_equity_fmt\": \"\u00a5473\u5104\", \"total_debt\": 38105000000.0, \"total_debt_fmt\": \"\u00a5381\u5104\", \"total_cash\": 13196000000.0, \"total_cash_fmt\": \"\u00a5132\u5104\", \"equity_ratio\": 45.15, \"de_ratio\": 0.8, \"current_ratio\": 1.18, \"operating_cf\": -5791000000.0, \"operating_cf_fmt\": \"-\u00a558\u5104\", \"investing_cf\": -9569000000.0, \"investing_cf_fmt\": \"-\u00a596\u5104\", \"financing_cf\": 9736000000.0, \"financing_cf_fmt\": \"\u00a597\u5104\", \"free_cf\": -15458000000.0, \"free_cf_fmt\": \"-\u00a5155\u5104\", \"net_margin\": -13.49, \"roe\": -9.42, \"roa\": -4.25}, {\"year\": 2024, \"revenue\": 42871000000.0, \"revenue_fmt\": \"\u00a5429\u5104\", \"gross_profit\": 31251000000.0, \"gross_profit_fmt\": \"\u00a5313\u5104\", \"operating_income\": 7532000000.0, \"operating_income_fmt\": \"\u00a575\u5104\", \"ebit\": 7330000000.0, \"ebit_fmt\": \"\u00a573\u5104\", \"net_income\": 5507000000.0, \"net_income_fmt\": \"\u00a555\u5104\", \"eps\": 43.92, \"operating_margin\": 17.57, \"total_assets\": 102226000000.0, \"total_assets_fmt\": \"\u00a51022\u5104\", \"total_equity\": 56176000000.0, \"total_equity_fmt\": \"\u00a5562\u5104\", \"total_debt\": 23300000000.0, \"total_debt_fmt\": \"\u00a5233\u5104\", \"total_cash\": 18756000000.0, \"total_cash_fmt\": \"\u00a5188\u5104\", \"equity_ratio\": 54.95, \"de_ratio\": 0.41, \"current_ratio\": 1.91, \"operating_cf\": 9312000000.0, \"operating_cf_fmt\": \"\u00a593\u5104\", \"investing_cf\": -2690000000.0, \"investing_cf_fmt\": \"-\u00a527\u5104\", \"financing_cf\": -2031000000.0, \"financing_cf_fmt\": \"-\u00a520\u5104\", \"free_cf\": 7786000000.0, \"free_cf_fmt\": \"\u00a578\u5104\", \"net_margin\": 12.85, \"roe\": 9.8, \"roa\": 5.39}, {\"year\": 2023, \"revenue\": 34343000000.0, \"revenue_fmt\": \"\u00a5343\u5104\", \"gross_profit\": 25456000000.0, \"gross_profit_fmt\": \"\u00a5255\u5104\", \"operating_income\": 4976000000.0, \"operating_income_fmt\": \"\u00a550\u5104\", \"ebit\": 5456000000.0, \"ebit_fmt\": \"\u00a555\u5104\", \"net_income\": 3772000000.0, \"net_income_fmt\": \"\u00a538\u5104\", \"eps\": 30.22, \"operating_margin\": 14.49, \"total_assets\": 94937000000.0, \"total_assets_fmt\": \"\u00a5949\u5104\", \"total_equity\": 52161000000.0, \"total_equity_fmt\": \"\u00a5522\u5104\", \"total_debt\": 22800000000.0, \"total_debt_fmt\": \"\u00a5228\u5104\", \"total_cash\": 13278000000.0, \"total_cash_fmt\": \"\u00a5133\u5104\", \"equity_ratio\": 54.94, \"de_ratio\": 0.44, \"current_ratio\": 1.34, \"operating_cf\": -5500000000.0, \"operating_cf_fmt\": \"-\u00a555\u5104\", \"investing_cf\": -15002000000.0, \"investing_cf_fmt\": \"-\u00a5150\u5104\", \"financing_cf\": 1948000000.0, \"financing_cf_fmt\": \"\u00a519\u5104\", \"free_cf\": -14060000000.0, \"free_cf_fmt\": \"-\u00a5141\u5104\", \"net_margin\": 10.98, \"roe\": 7.23, \"roa\": 3.97}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 22.0}, {\"year\": 2023, \"amount\": 20.0}, {\"year\": 2024, \"amount\": 20.0}, {\"year\": 2025, \"amount\": 20.0}, {\"year\": 2026, \"amount\": 10.0}], \"latest\": 10.0, \"has_data\": true}}","ma_5_value":702.39999999999998,"ma_5_deviation":0.65000000000000002,"ma_5_trend":"up","ma_25_value":722.91999999999996,"ma_25_deviation":-2.2000000000000002,"ma_25_trend":"down","ma_75_value":666.92999999999995,"ma_75_deviation":6.0099999999999998,"ma_75_trend":"up","ma_200_value":588.63,"ma_200_deviation":20.109999999999999,"ma_200_trend":"up","previousClose":710,"open":712,"dayHigh":718,"dayLow":695,"volume":556100,"averageVolume":1030742,"revenueGrowth":0},"sector":[],"class_list":["post-9680","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>JCR PHARMACEUTICAL CO - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4552\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4552\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4552\/\",\"name\":\"JCR PHARMACEUTICAL CO - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-28T13:29:45+00:00\",\"dateModified\":\"2026-08-23T04:45:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4552\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4552\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4552\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JCR PHARMACEUTICAL CO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"JCR PHARMACEUTICAL CO - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4552\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4552\/","url":"https:\/\/japanir.jp\/en\/company\/company-4552\/","name":"JCR PHARMACEUTICAL CO - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-28T13:29:45+00:00","dateModified":"2026-08-23T04:45:13+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4552\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4552\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4552\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"JCR PHARMACEUTICAL CO"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/9680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=9680"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=9680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}